FDA Requests Antidepressant Labeling Add Warning On Suicidality
This article was originally published in The Pink Sheet Daily
Executive Summary
The public health advisory and labeling change request follows an advisory committee recommendation for a stronger warning on the possible risks of the medications. The warning encourages health care providers to monitor patients closely for suicidal behavior although a link between the medications and suicide has not been established.
You may also be interested in...
UK Declines To Prosecute GSK Over Paxil Risk Information
MHRA determines law was insufficient to warrant criminal prosecution.
UK Declines To Prosecute GSK Over Paxil Risk Information
MHRA determines law was insufficient to warrant criminal prosecution.
Pfizer Zoloft Ad Cited By FDA For Omitting Suicide Risk
FDA's ad review division objects to an October print ad for the antidepressant that failed to mention the risk of suicidality and clinical worsening. The ad's brief summary referenced information from outdated labeling, the agency says.